MDxHealth SA (MDXH) is a multinational healthcare company known for its specialization in the development and marketing of advanced molecular diagnostic products and services. Founded in 2003 and headquartered in Herstal, Belgium, MDxHealth is a pace setter in the field of epigenetics and molecular diagnostics, targeting various cancer types like prostate, bladder, and brain cancer.
MDxHealth SA aims primarily to provide doctors, clinicians and their patients with actionable information that enhances the care and treatment of urological cancer through its testing methodologies. The company boasts a suite of innovative products ranging from ConfirmMDx, which aids in the detection of prostate cancer, to SelectMDx that helps determine the aggressiveness of the disease and necessity of a biopsy.
A key element of MDxHealth's success story lies in its commitment to research and development, underlined by extensive partnerships with academic, clinical and pharmaceutical entities. The company's testing methods rely predominantly on DNA Methylation, considered a significant facet of epigenetics. This process enables MDxHealth to detect genetic changes that can signal potential cancers at an early stage, providing the opportunity for earlier treatment with potentially better outcomes.
MDxHealth has assembled an impressive network, expanding its diagnostics presence across Europe and the United States. The company operates various state-of-the-art laboratories, such as those in Nijmegen, Netherlands, and Irvine, California. These facilities support the global reach and accessibility of MDxHealth's cutting-edge molecular diagnostic products.
The company made a significant impact on healthcare through its commitment to personalized medicine, fostering improved patient outcomes through early intervention and diagnosis. Not only does the company develop and deliver life-changing diagnostic products and services, but it also aids in reducing unnecessary invasive procedures, decreasing patient anxiety and ensuring more effective resource allocation in healthcare delivery.
MDxHealth’s clinical prowess, innovative solutions and strong collaborations have firmly established it as a global leader in the field of molecular diagnostics. Its products and services have revolutionized the approach to diagnosing and treating urological cancers, changing the healthcare landscape while providing hope and reassurance for patients worldwide.
With a reputation for breaking boundaries in patient testing and cancer detection, MDxHealth SA continues to contribute significantly to progressive changes in global healthcare. The company remains committed to its mission – helping physicians diagnose cancer earlier and more accurately thus enhancing the life chances of patients.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
BTIG has lowered its price target for MDxHealth SA (NASDAQ:MDXH) shares from $4.00 to $2.00, while maintaining a Buy rating. This adjustment follows the company's second-quarter results and a recent $20 million stock offering that increased the share count. MDxHealth also reported strong Q2 revenue growth, surpassed analyst expectations, and resolved a significant Medicare recoupment claim related to its discontinued Resolve business.
MDxHealth reported a strong Q2 2026, with revenue increasing 16% year over year to $27.2 million, driven by growth in prostate cancer diagnostics and a 14% sequential increase. The company successfully transitioned its sales force, discontinued the Resolve UTI business, and eliminated a $10.4 million contingent liability, strengthening its balance sheet with a $20 million financing. Management is confident in achieving its full-year revenue guidance of $110 million-$115 million and returning to positive adjusted EBITDA by the end of 2026.
MDxHealth reported mixed second-quarter earnings with a loss of 18 cents per share, missing consensus, but sales rose 16% to $27.20 million, beating expectations. The company reaffirmed its 2026 sales guidance of $110 million-$115 million and expects to return to positive adjusted EBITDA by the end of 2026, driven by accelerating tissue growth and strategic initiatives. Following the report, MDxHealth's stock surged by 127.25%.